Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
26.24 USD | +0.27% | +8.05% | -13.32% |
May. 09 | Intellia Therapeutics' Q1 Net Loss Narrows, Collaboration Revenue Rises | MT |
May. 09 | Transcript : Intellia Therapeutics, Inc., Q1 2024 Earnings Call, May 09, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-13.32% | 2.52B | |
+33.93% | 50.85B | |
+0.26% | 42.82B | |
+49.62% | 42.03B | |
-4.96% | 29.55B | |
+10.74% | 26.11B | |
-22.16% | 19.13B | |
+8.67% | 13.05B | |
+27.06% | 12.16B | |
+24.38% | 12.08B |
- Stock Market
- Equities
- NTLA Stock
- News Intellia Therapeutics, Inc.
- Intellia Therapeutics Says Its Protein Disorder Treatment Candidate Showed Consistent Reduction of Plasma Protein in Phase 1 Trial